Trial Profile
Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms SPINART
- Sponsors Bayer
- 13 Aug 2015 According to a Bayer media release, 3-year analysis data (patient- and joint-level changes) from this study will be presented at the National Hemophilia Foundation's (NHF) 67th Annual Meeting.
- 04 Mar 2015 New trial record